

PROGRAM



8<sup>th</sup> INTERNATIONAL  
**ADRENAL  
CANCER  
SYMPOSIUM**

» VIRTUAL «  
CONFERENCE

BRESCIA  
**2021**

SEPTEMBER 30<sup>TH</sup> - OCTOBER 1<sup>ST</sup> / 2<sup>ND</sup>

8<sup>th</sup> INTERNATIONAL  
**ADRENAL  
CANCER  
SYMPOSIUM**

---

---



## CONGRESS CHAIRMEN

### Alfredo Berruti

Department of Medical and Surgical Specialties,  
Radiological Sciences and Public Health,  
Medical Oncology  
University of Brescia, ASST-Spedali Civili, Brescia, Italy

### Massimo Terzolo

Internal Medicine, San Luigi Gonzaga Hospital,  
Orbassano  
Department of Clinical and Biological Sciences,  
University. Orbassano, Torino, Italy

## ORGANIZING SECRETARIAT

### Deborah Cosentini, Marta Laganà

Department of Medical and Surgical Specialties,  
Radiological Sciences and Public Health,  
Medical Oncology  
University of Brescia, ASST-Spedali Civili, Brescia, Italy

### Soraya Puglisi

Internal Medicine, San Luigi Gonzaga Hospital,  
Orbassano  
Department of Clinical and Biological Sciences,  
University. Orbassano, Torino, Italy

## LOCAL ORGANIZING COMMITTEE

Roberta Ambrosini

Maurizio Castellano

Maria Beatrice Panarotto

Pietro Luigi Poliani

Francesco Porphiglia

Sandra Sigala

Guido Alberto Massimo Tiberio

Andrea Veltri

Marco Volante

## SCIENTIFIC COMMITTEE

Wiebke Art

Giullame Assiè

Irina Bancos

Maria Candida Barisson Villares Fragoso

Eric Baudin

Jérôme Bertherat

Felix Beuschlein

Martin Faßnacht-Capeller

Thomas Giordano

Assie Guillaume

Mouhammed Habra

Gary Hammer

Haak Harm

Péter Igaz

Darko Kastelan

Electron Kebebew

Matthias Kroiss

Andre Lacroix

Enzo Lalli

Michaela Luconi

Bill Rainey

Cristina Ronchi

Hironobu Sasano

Carla Scaroni

Sandra Sigala

Britt Skogseid

Constantine Stratakis

Pierre Val

# 8<sup>th</sup> INTERNATIONAL ADRENAL CANCER SYMPOSIUM

ALL TIMES STATED IN CEST  
(Central European Summer Time)

## FACULTY

Wiebke Arlt	<i>Birmingham Uk</i>	Enzo Lalli	<i>Nice F</i>
Guillaume Assie'	<i>Paris F</i>	Jeff Lee	<i>Houston Usa</i>
Irina Bancos	<i>Rochester, Minnesota Usa</i>	Antonio Lerario	<i>Ann Arbor Usa</i>
Maria Candida Barisson Villares Fragoso	<i>San Paulo Br</i>	Alice Levine	<i>New York Usa</i>
Katie Basham	<i>Salt Lake City Usa</i>	Rossella Libe'	<i>Paris F</i>
Eric Baudin	<i>Villejuif F</i>	Michaela Luconi	<i>Firenze Ita</i>
Alfredo Berruti	<i>Brescia Ita</i>	Massimo Mannelli	<i>Firenze Ita</i>
Jerome Bertherat	<i>Paris F</i>	Franco Mantero	<i>Padova Ita</i>
Felix Beuschlein	<i>Zürich Ch</i>	Giampiero Mazzaglia	<i>Monza Ita</i>
Isabelle Bourdeau	<i>Montreal Can</i>	Radu Mihai	<i>Oxford Uk</i>
Paolo Bruzzi	<i>Genova Ita</i>	Barbra Miller	<i>Ann Arbor Usa</i>
Maurizio Castellano	<i>Brescia Ita</i>	Dipika Mohan	<i>Ann Arbor Usa</i>
Nadia Cherradi	<i>Grenoble F</i>	Emilia Pinto	<i>Memphis Usa</i>
Deborah Cosentini	<i>Brescia Ita</i>	Francesco Porpiglia	<i>Orbassano Ita</i>
Joakim Crona	<i>Uppsala Se</i>	Soraya Puglisi	<i>Orbassano Ita</i>
Ronald De Krijger	<i>Utrecht Nl</i>	Raul C. Ribeiro	<i>Memphis Usa</i>
Tobias Else	<i>Ann Arbor Usa</i>	Cristina Ronchi	<i>Birmingham Uk</i>
Martin Fassnacht	<i>Würzburg De</i>	Charles Roux	<i>Villejuif F</i>
Matthieu Faron	<i>Villejuif F</i>	Ohk-Hyun Ryu	<i>Seoul Kr</i>
Thomas Giordano	<i>Ann Arbor Usa</i>	Hironobu Sasano	<i>Sendai Jpn</i>
Harm Haak	<i>Enndhoven Nl</i>	Silviu Sbiera	<i>Würzburg De</i>
Mouhammed Habra	<i>Houston Usa</i>	Sandra Sigala	<i>Brescia Ita</i>
Julien Hadoux	<i>Villejuif F</i>	Britt Skogseid	<i>Uppsala Se</i>
Gary Hammer	<i>Ann Arbor Usa</i>	Constantine Stratakis	<i>Bethesda Usa</i>
Constanze Hantel	<i>Zürich Ch</i>	Rebecca Steenaard	<i>Eindhoven Nl</i>
Ana Hoff	<i>Sao Paulo Br</i>	Antoine Tabarin	<i>Bordeaux F</i>
Peter Igaz	<i>Budapest H</i>	Massimo Terzolo	<i>Orbassano Ita</i>
Darko Kastelan	<i>Zagreb Hr</i>	Guido Tiberio	<i>Brescia Ita</i>
Katia Kiseljak-Vassiliades	<i>Aurora Usa</i>	Pierre Val	<i>Clermont Ferrand F</i>
Electron Kebebew	<i>Stanford Usa</i>	Marco Volante	<i>Orbassano Ita</i>
Otilia Kimpel	<i>Würzburg De</i>	William Young	<i>Rochester Usa</i>
Matthias Kroiss	<i>Münich De</i>		
Andre' Lacroix	<i>Montreal Can</i>		

ALL TIMES STATED IN CEST  
(Central European Summer Time)

## PROGRAM September 30<sup>TH</sup>

1.30 - 02.00 pm **Welcome** - *Alfredo Berruti & Massimo Terzolo*

2.00 - 3.10 pm **I Session - Molecular heterogeneity of adrenocortical tumors** - *Chairmen: Marco Volante, Hironobu Sasano*

2.00 - 2.12	Venturing through transcriptional and epigenetic lands of adrenocortical tumors - Antonio Lerario, Michigan University
2.12 - 2.24	DNA-based markers as a window on intratumor heterogeneity Guillaume Assié, Cochin Hospital
2.24 - 2.36	Cellular senescence in adrenal homeostasis and cancer Katie Basham, Huntsman Cancer Institute, University Utah
2.36 - 2.48	Liquid biopsy in the assessment of adrenocortical carcinoma heterogeneity: where are we now? - Peter Igaz, Semmelweis University
2.48 - 3.10	<b>Discussion</b>
3.10 - 3.20	<b>Break</b>

3.20 - 4.40 pm **II Session - From Bench to bedside: new insights from preclinical studies** - *Chairmen: Michaela Luconi, Emilia Pinto*

3.20 - 3.32	PRC2 stabilizes a differentiated cell state required for sustained proliferation in ACC - Dipika Mohan, Michigan University
3.32 - 3.44	Combined inactivation of ZNRF3 and TP53 alter the immune microenvironment and favor ACC development Pierre Val, French National Centre for Scientific Research Hospital
3.44 - 3.56	Adrenocortical carcinoma xenograft in zebrafish embryos as a model to study in vivo cytotoxicity of molecular target agents Sandra Sigala, University of Brescia
3.56 - 4.08	How to treat ACC by targeting lipid metabolism and ferroptosis Matthias Kroiss, University of Munich
4.08 - 4.20	Targeting cytoskeleton dynamics against metastatic dissemination in ACC - Enzo Lalli, French Institute of Health and Medical Research

# 8<sup>th</sup> INTERNATIONAL ADRENAL CANCER SYMPOSIUM

ALL TIMES STATED IN CEST  
(Central European Summer Time)

## PROGRAM September 30<sup>TH</sup>

4.20 - 4.40 **Discussion**

4.40 - 4.50 **Break**

### Keynote lecture

4.50 - 5.20 pm

*Chairmen: Harm Haak, Jerome Bertherat*

Translating the results of preclinical research to clinics  
*Gary Hammer, Michigan University*

*Chairman: Massimo Terzolo*

5.20 - 5.30 pm

LET'S CURE ACC: an international association for ACC patients, caregivers, and medical experts.  
*Sandra Bouarroudj, Catherine Lamy*  
Co-presidents of the association LetsCureACC

5.30 - 8.00 pm

### Proffered papers on preclinical studies in ACC

*Chairmen: Nadia Cherradi, Thomas Giordano*

5.30 - 5.40

Mapping of Immunotherapeutic Vulnerabilities in Adrenocortical Carcinoma  
*K.S. BORGES, D.T. Breault.*  
Division of Endocrinology, Boston Children's Hospital, Boston, MA, 02115, USA.  
Department of Pediatrics, Harvard Medical School, Boston, MA, 02115, USA.

5.40 - 5.50

MicroRNA therapeutics in ACC: A lipid nanoparticle-based approach to suppress the oncogenic activity of microRNAs  
*S. REDA EL SAYED<sup>o</sup>, A. Nougarede<sup>^</sup>, J. Denis<sup>o</sup>, J. Cristante<sup>o</sup>, O. Chabre<sup>o\*</sup>, L. Guyon<sup>o</sup>, F. Navarro<sup>^</sup> and N. Cherradi<sup>o</sup>*  
<sup>o</sup> University Grenoble Alpes, INSERM, CEA, IRIG, Biology and Biotechnologies for Health Lab, UMR\_1292, Grenoble, France  
<sup>^</sup> University Grenoble Alpes, CEA, LETI, Technologies for Healthcare and Biology Division, Microfluidic Systems and Bioengineering Lab, Grenoble, FRANCE.  
<sup>\*</sup> University Hospital Grenoble Alpes, Endocrinology Department, Grenoble, France

5.50 - 6.00

Estrogen-Like effect of mitotane explained by its agonist activity on estrogen receptor- $\alpha$   
*ELISA ROSSINI 1, Edoardo Giacobuzzi 2,3, Fabrizio Gangemi 4, Mariangela Tamburello 1, Deborah Cosentini 5, Andrea Abate 1, Marta Laganà 5, Alfredo Berruti 5, Salvatore Grisanti 5 and Sandra Sigala 1*  
1 Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy; 2 Wellcome Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK; 3 National Institute for Health Research Oxford Biomedical Research Centre, Oxford OX4 2PG, UK; 4 Unit of Physics, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy; 5 Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia at A.S.S.T. Spedali Civili di Brescia, 25123 Brescia, Italy.

## PROGRAM September 30<sup>TH</sup>

- 6.00 - 6.10
- Effect of ribociclib alone or in combination with progesterone and/or mitotane in in vitro experimental acc cell model.  
*ANDREA ABATE*<sup>1</sup>, *Elisa Rossini*<sup>1</sup>, *Mariangela Tamburello*<sup>1</sup>, *Marta Laganà*<sup>2</sup>, *Deborah Cosentini*<sup>2</sup>, *Salvatore Grisanti*<sup>2</sup>, *Chiara Fiorentini*<sup>1</sup>, *Guido A.M. Tiberio*<sup>3</sup>, *Maria Scatolini*<sup>4</sup>, *Enrico Grosso*<sup>4</sup>, *Constanze Hantel*<sup>5,6</sup>, *Maurizio Memo*<sup>1</sup>, *Alfredo Berruti*<sup>2</sup>, *Sandra Sigala*<sup>1</sup>  
1Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy. 2Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia and ASST Spedali Civili di Brescia, 25123 Brescia, Italy. 3Surgical Clinic, Department of Clinical and Experimental Sciences, University of Brescia at ASST Spedali Civili di Brescia, 25123 Brescia, Italy. 4Molecular Oncology Laboratory, "Edo ed Elvo Tempia" Foundation, Ponderano, 13875, Biella, Italy. 5Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH), Zurich, Switzerland. 6Medizinische Klinik und Poliklinik III, University Hospital Carl Gustav Carus Dresden, Dresden, Germany.
- 6.10 - 6.20
- Trabectedin Reduces Cell Invasiveness And Metastasis Formation In In Vitro And In Vivo Models Of Adrenocortical Carcinoma  
*Andrea Abate*<sup>1</sup>, *MARIANGELA TAMBURELLO*<sup>1</sup>, *Elisa Rossini*<sup>1</sup>, *Deborah Cosentini*<sup>2</sup>, *Marta Laganà*<sup>2</sup>, *Antonella Turla*<sup>2</sup>, *Ram Manohar Basnet*<sup>3</sup>, *Daniela Zizioli*<sup>3</sup>, *Constanze Hantel*<sup>4,5</sup>, *Guido A.M. Tiberio*<sup>6</sup>, *Salvatore Grisanti*<sup>2</sup>, *Alfredo Berruti*<sup>2</sup>, *Sandra Sigala*<sup>1</sup>  
1 Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy;  
2 Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia at ASST Spedali Civili di Brescia, 25123 Brescia, Italy;  
3 Section of Biotechnology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy;  
4 Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH) Zurich, Switzerland;  
5 Medizinische Klinik und Poliklinik III, University Hospital Carl Gustav Carus Dresden, Germany;  
6 Surgical Clinic, Department of Clinical and Experimental Sciences, University of Brescia at ASST Spedali Civili di Brescia, 25123 Brescia, Italy.
- 6.20 - 6.30
- Cancer paracrine expression of CXCL12 limits cancer progression in Adrenocortical Carcinoma and mediates anti-cancer action of rosiglitazone  
*G. CANTINI*<sup>\*</sup>, *L. Fei*<sup>\*</sup>, *L. Canu*<sup>\*</sup>, *E. Lazzeri*<sup>\*</sup>, *M. Sottili*<sup>\*</sup>, *M. Francalanci*<sup>^</sup>, *M.L. Angelotti*<sup>\*</sup>, *G. De Filipo*<sup>\*</sup>, *T. Ercolino*<sup>\*</sup>, *S. Gelmini*<sup>\*</sup>, *M. Mangoni*<sup>\*</sup>, *G. Nesi*<sup>§</sup>, *M. Mannelli*<sup>\*</sup>, *M. Maggi*<sup>\*</sup>, *M. Luconi*<sup>\*</sup>  
<sup>\*</sup> Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy  
<sup>^</sup> Meyer Children's Hospital, Florence, Italy  
<sup>o</sup> Azienda Ospedaliero-Universitaria Careggi, Florence, Italy  
<sup>§</sup> Department of Health Sciences, University of Florence, Florence, Italy
- 6.30 - 6.40
- Activated WNT/Beta-Catenin pathway regulates the expression of a subset of microRNAs in adrenocortical carcinoma  
*J. CRISTANTE*<sup>o</sup>, *L. Guyon*<sup>o</sup>, *J. Denis*<sup>o</sup>, *S. Reda El Sayed*<sup>o</sup>, *B. Ragazzan*<sup>^</sup>, *O. Chabre*<sup>o\*</sup>, *N. Cherradi*<sup>o</sup>  
<sup>o</sup> University Grenoble Alpes, INSERM, CEA, IIRIG, Biology and Biotechnologies for Health Lab, UMR\_1292, Grenoble, France  
<sup>^</sup> Institut Cochin, INSERM U1016, CNRS UMR8104, Paris Descartes University, Paris, France  
<sup>\*</sup> University Hospital Grenoble Alpes, Endocrinology Department, Grenoble, France
- 6.40 - 6.45
- Analysis of the role of Mst1 and Mst2 in adrenal cortex homeostasis in a transgenic mouse model  
*N. ABOU NADER*<sup>\*</sup>, *É. Blais*<sup>\*</sup>, *G. St-Jean*<sup>\*</sup>, *D. Boerboom*<sup>\*</sup>, *G. Zamberlam*<sup>\*</sup>, *A. Boyer*<sup>\*</sup>  
Center of Research in Reproduction and Fertility, Faculty of veterinary medicine, University of Montreal, Saint-Hyacinthe, Canada J2S 2M2

# 8<sup>th</sup> INTERNATIONAL ADRENAL CANCER SYMPOSIUM

ALL TIMES STATED IN CEST  
(Central European Summer Time)

## PROGRAM September 30<sup>TH</sup>

6.45 - 6.50	<p>Investigation of steroidogenesis related targets and electrophysiological responsiveness in experimental cell models of Adrenocortical Carcinoma.  <i>C. BOTHOU 1, S. Gut 1, D. Penton 2, M. Peitzsch 3, SR. Bornstein 3,4,5,6,7, A. Berutti 8, S. Sigala 9, C. Hantel 1,3</i>            1 Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH), Zürich, Switzerland            2 Electrophysiology Facility (e-phac), Department of Molecular Life Sciences, University of Zurich (UZH), Zürich, Switzerland            3 Medizinische Klinik und Poliklinik III, University Hospital Carl Gustav Carus Dresden, Dresden, Germany            4 Diabetes and Nutritional Sciences, King's College London, WC2R 2LS London, United Kingdom.            5 Center for Regenerative Therapies, Technische Universität Dresden, 01307 Dresden, Germany.            6 Paul-Langerhans-Institute Dresden, Helmholtz Center Munich, University Hospital Carl Gustav Carus, Faculty of Medicine, Technische Universität Dresden, 01307 Dresden, Germany.            7 Lee Kong Chian School of Medicine, Nanyang Technological University, 636921 Singapore.            8 Medical Oncology Unit, Azienda Socio Sanitaria Territoriale (ASST) Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy            9 Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy</p>
6.50 - 6.55	<p>Identification of small molecule inhibitors of VAV2, an essential driver of ACC malignancy  <i>C. RUGGIERO*#, C. Derviaux*¶, P. Roche*¶, X. Morelli*¶, E. Lalli*#§</i>            *Institut de Pharmacologie Moléculaire et Cellulaire, Université Côte d'Azur, CNRS, 660 route des Lucioles-Sophia Antipolis, 06560 Valbonne, France; #NEOGENEX-CANCER CNRS International Associated Laboratory, 660 route des Lucioles, Sophia Antipolis, 06560 Valbonne, France; °CNRS, Inserm, Institut Paoli-Calmettes, Aix-Marseille Univ, CRCM, Marseille, France; ¶Institut Paoli-Calmettes, HITS platform, Marseille, France; §Inserm, Institut de Pharmacologie Moléculaire et Cellulaire, 660 route des Lucioles - Sophia Antipolis, 06560 Valbonne, France.</p>
6.55 - 7.00	<p>Canonical TGF-beta activation as a potential regulator of adrenocortical cancer cell growth  <i>L.C. VERONEZ*, C.A.P. Corrêa^, R.C.P. Lira°, P. Chagas^, K.R. Silva^, M. Baroni^, L.F. Nagano^, J.A. Yunes+, S.R. Brandalise+, S. Tucci#, S.R. Antonini*, R.G.P. Queiroz*, L.G. Tone*, C.A. Scideli*</i>            *Department of Pediatrics, ^Department of Genetics, and #Department of Surgery, Ribeirao Preto Medical School - University of Sao Paulo, Ribeirao Preto/SP, Brazil; °Centro Universitário CESMAC - Maceió/AL, Brasil; +Centro Infantil Boldrini - Campinas/SP, Brazil.</p>
7.00 - 7.05	<p>The different contribution of IGF1R and IR in mediating insulin-like growth factor 2 (IGF2) effects in adrenocortical carcinomas  <i>R. CATALANO*, A.M. Barbieri*, D. Treppiedi*, F. Mangili*, G. Di Muro*, G. Marra*, E. Esposito*, V. Morelli^, M. Arosio*,^, G. Mantovani*,^, E. Peverelli*</i>            *Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; ^ Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</p>
7.05 - 7.10	<p>Targeting the actin bundling protein FSCN1 as a novel therapeutic tool for metastatic ACC  <i>C. RUGGIERO*#, E. Josselin°, R. Castellano°, M. Luconi^, Y. Collette° &amp; E. Lalli*#¶</i>            *Institut de Pharmacologie Moléculaire et Cellulaire, Université Côte d'Azur, CNRS, 660 route des Lucioles-Sophia Antipolis, 06560 Valbonne, France; #NEOGENEX-CANCER CNRS International Associated Laboratory, 660 route des Lucioles, Sophia Antipolis, 06560 Valbonne, France; °CNRS, Inserm, Institut Paoli-Calmettes, Aix-Marseille Univ, CRCM, Marseille, France; ^ Endocrinology Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy; ¶Inserm, Institut de Pharmacologie Moléculaire et Cellulaire, 660 route des Lucioles - Sophia Antipolis, 06560 Valbonne, France.</p>
7.10 - 7.15	<p>Re-Evaluation of Combinational Efficacy and Synergy of the Italian Protocol In Vitro: Are We Truly Optimizing Benefit or Permitting Unwanted Toxicity?  <i>Chitra Subramanian (1), Reid McCallister (1), Dawn Kuszyński (1), and MARK S. COHEN, MD, FACS (1,2,3)</i>            1 Department of Surgery, Michigan Medicine, Ann Arbor, MI 48109, USA            2 Department of Pharmacology, University of Michigan, Ann Arbor, MI 48109, USA            3 Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA</p>
7.15 - 8.00	<p><b>Discussion</b></p>



ALL TIMES STATED IN CEST  
(Central European Summer Time)

## PROGRAM October 1<sup>ST</sup>

### 2.00 - 3.10 pm **I Session - Progress in surgical treatment of adrenocortical carcinoma** - Chairmen: *Barbra Miller, Radu Mihai*

2.00 - 2.12	Laparoscopic surgery for all, for some, or for none? <i>Francesco Porpiglia, University of Torino</i>
2.12 - 2.24	Why R0 resection is not attained in all patients? <i>Jeff Lee, MD Anderson Cancer Center</i>
2.24 - 2.36	Surgery in metastatic adrenocortical carcinoma: when and why? <i>Electron Kebebew, Stanford University</i>
2.36 - 2.48	Hyperthermic intraperitoneal chemotherapy and conversion surgery: rationale and results - <i>Guido Tiberio, University of Brescia</i>
2.48 - 3.10	<b>Discussion</b>
3.10 - 3.20	<b>Break</b>

### 3.20 - 4.30 pm **II Session - Adjuvant Therapies** Chairmen: *André Lacroix, William Young*

3.20 - 3.32	How the Adiuvo trial may change clinical practice <i>Massimo Terzolo, University of Torino</i>
3.32 - 3.44	Predictive factors of adjuvant mitotane therapy <i>Isabelle Bourdeau, CHUM Research Center</i>
3.44 - 3.56	Adjuvant chemotherapy: is it worth a try? <i>Otilia Kimpel, Würzburg University</i>
3.56 - 4.08	Adjuvant radiotherapy: new life in an old concept <i>Tobias Else, Michigan University</i>
4.08 - 4.30	<b>Discussion</b>
4.30 - 4.40	<b>Break</b>

### 4.40 - 5.10 pm **Keynote lecture** Chairmen: *Britt Skogseid, Constantine Stratakis* Medical treatment for ACC: a critical view on the past, present and future - *Martin Fassnacht, Würzburg University*

# 8<sup>th</sup> INTERNATIONAL ADRENAL CANCER SYMPOSIUM

ALL TIMES STATED IN CEST  
(Central European Summer Time)

## PROGRAM October 1<sup>ST</sup>

### 5.10 - 8.00 pm **Proffered papers on clinical studies in ACC** *Chairmen: Maria-Candida Barisson Villares Frago, Darko Kastelan*

- 5.10 - 5.20  
Circulating cell-free DNA as a biomarker for disease surveillance in adrenocortical carcinoma  
*\*JULIANE LIPPERT, ^Gabrielle Smith, \*Barbara Altieri, ^Yasir S. Elhassan, \*Laura-Sophie Landwehr, ^Alessandro Prete, °Silke Appenzeller, ^Vasileios Chortis, \*Sonja Steinhauer, †Miriam Asia, ‡Robert P. Sutcliffe, ^Wiebke Art, \*Martin Fassnacht, \* ^Cristina L. Ronchi*  
*\*Division of Endocrinology and Diabetes, University Hospital of Wuerzburg (Germany), ^Institute of Metabolism and System Research, University of Birmingham (UK) °Bioinformatics Core Unit, Comprehensive Cancer Centre Mainfranken, University Hospital of Wuerzburg (Germany) †Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust (UK) ‡Hepatobiliary Surgery, Queen Elizabeth Hospital, University Hospitals Birmingham (UK)*
- 5.20 - 5.30  
Transcriptome profiles in formalin-fixed paraffin-embedded samples for the diagnosis and prognosis of adrenocortical carcinoma  
*A. JOUINOT\*, J. Lippert^, M. Sibony\*, F. Violon\*, L. Jeanpierre\*, D. De Murat\*, R. Armignacco\*, A. Septier\*, K. Perlemoine\*, F. Letourneur\*, B. Izac\*, B. Ragazzon\*, K. Leroy\*, E. Pasmant\*, M.O. North\*, S. Gaujoux\*, B. Dousset\*, L. Groussin\*, R. Libe\*, B. Terris\*, M. Fassnacht^, C.L. Ronchi^, °, J. Bertherat\*, G. Assie\**  
*\* Institut Cochin, Paris University, INSERM, CNRS, Paris, France ^ Dept of Internal Medicine I, Div. of Endocrinology and Diabetes, University Hospital, University of Wuerzburg, Wuerzburg, Germany ° Institute of Metabolism and System Research, University of Birmingham, Birmingham, UK*
- 5.30 - 5.40  
Adverse events associated with mitotane monotherapy in patients with adrenocortical carcinoma.  
*B. ALTIERI\*, M. Detomas\*, O. Kimpel\*, M. Quinkler^, L. Canu°, M. Mannelli°, A. Angelousi#, G. Kaltsas#, Y.S. Elhassan†, S. Della Casa§, M.C. De Martinoli, F. Megerle\*, C.L. Ronchi\*, †, M. Kroiss\*, ‡, M. Fassnacht\*.*  
*\*Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital of Würzburg, Würzburg, Germany. ^Endocrinology in Charlottenburg, Berlin, Germany. °Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy. #1st Propaedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece. †Institute of Metabolism and System Research, University of Birmingham and Centre for Endocrinology, Diabetes and Metabolism (CEDAM), Birmingham, UK. §Division of Endocrinology and Metabolism, Catholic University of the Sacred Heart, Rome, Italy. ††Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy. ‡Medizinische Klinik und Poliklinik IV, Ludwig-Maximilians-Universität München, Germany.*
- 5.40 - 5.50  
Expression of PD-1 and PD-L1 immune checkpoints and its prognostic impact on adrenocortical carcinoma  
*L.S LANDWEHR\*, I. Sbierra\*, B. Altieri\*, H. Remde\*, S. Kircher#, S. Sbierra\*^, M. Kroiss\*^+, M. Fassnacht\*^°*  
*\* Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital Würzburg, Würzburg, Germany ^ Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg, Germany, ° Clinical Chemistry and Laboratory Medicine, University Hospital Würzburg, Würzburg, Germany # Institute of Pathology, University of Würzburg, Würzburg, Germany + Medizinische Klinik und Poliklinik IV, LMU Klinikum München, Ziemssenstr. 1, 80336, Munich, Germany*

## PROGRAM October 1<sup>ST</sup>

- 5.50 - 6.00  
Clinical, pathological and molecular characterization of adrenal cortical carcinomas with deficient mismatch repair status  
*VANESSA ZAMBELLI(1), Angelica D'Amelio(1), Ida Rapa(2), Giulia Trucco(2), Vittoria Basile(3), Susanna Cappia(1), Lorenzo Daniele(4), Giovanni De Rosa(4), Francesca Napoli(1), Mauro Papotti(1), Alfredo Berruti(5), Massimo Terzolo(3), Marco Volante(1)*  
1: Department of Oncology, University of Turin, Orbassano, Turin, Italy  
2: Pathology Unit, San Luigi Hospital, Orbassano, Turin, Italy  
3: Department of Clinical and Biological Sciences, Orbassano, Turin, Italy  
4: Pathology Unit, Mauriziano Hospital, Turin, Italy  
5: Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy
- 6.00 - 6.10  
Early mitotane discontinuation in patients with adrenocortical carcinoma  
*R.V. STEENAARD\*<sup>^</sup>, B.J.M. van der Bruggen\*, H.R. Haak\*<sup>^</sup>*  
\*Department of Internal Medicine, Máxima MC, Eindhoven/Veldhoven, the Netherlands.  
^Maastricht University, CAPHRI School for Public Health and Primary Care, Ageing and Long-Term Care, Maastricht, the Netherlands.  
\*Department of Internal Medicine, Maastricht University Medical Centre+, Maastricht, the Netherlands.
- 6.10 - 6.20  
Outcome of patients with adrenocortical cancer in Italy: a population-based study.  
*SORAYA PUGLISI#, Anna Calabrese#, Francesco Ferraiù\*, Antonella Violi\*, Marta Laganà\$, Salvatore Grisanti\$, Filippo Ceccato+, Carla Scaroni+, Guido Di Dalmazi%, Antonio Stigliano£, Barbara Altieri^, Letizia Canu°, Paola Loli@, Rosario Pivonello\$, Emanuela Arvatç, Valentina Morelli//, Vittoria Basile#, Paola Berchiolla#, Alfredo Berruti\$, Salvatore Cannavo\*, Massimo Terzolo#.*  
#Internal Medicine, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.  
\*Endocrine Unit of University Hospital of Messina, University of Messina, Italy.  
\$Oncology Unit, University of Brescia, Brescia, Italy.  
+Endocrinology Unit, Department of Medicine DIMED, University-Hospital of Padua, Italy.  
%Division of Endocrinology, Department of Medical and Surgical Sciences, Alma Mater University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy.  
£Endocrinology, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Italy.  
^Division of Endocrinology and Metabolic Diseases, University-Hospital Gemelli, IRCCS, Catholic University of the Sacred Heart, Rome, Italy.  
°Endocrinology Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Italy.  
@Endocrinology, Hospital Niguarda Ca' Granda, Milan, Italy.  
çEndocrinology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Italy.  
çDepartment of Medical Sciences, University of Turin, Turin, Italy.  
//Endocrinology Unit, Department of Clinical Sciences and Community Health, University of Milan and Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano.  
&Statistical Unit, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.
- 6.20 - 6.30  
New Onset of Hypothyroidism is Frequent During Mitotane Therapy in Adrenocortical Cancer: New Data on Prevalence and Timeline  
*J. POIRIER\*, S Godelme<sup>^</sup>, A Mourot\*, S Grunenwald<sup>^</sup>, A Lacroix\*, P Caron<sup>^</sup>, and I Bourdeau\**  
\*Division of Endocrinology, Department of Medicine and Research Center, Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada  
^Service d'Endocrinologie, Maladies métaboliques et Nutrition, Pôle Cardio-Vasculaire et Métabolique, Centre hospitalo-Universitaire de Toulouse, France

# 8<sup>th</sup> INTERNATIONAL ADRENAL CANCER SYMPOSIUM

ALL TIMES STATED IN CEST  
(Central European Summer Time)

## PROGRAM October 1<sup>ST</sup>

- 6.30 - 6.40  
Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients' Survival  
*VICTOR SGROUGI, MD1,2, Irina Bancos, MD3, Marilyne Daher4, Jeffrey E. Lee, MD5, Paul H. Graham, MD5, Jose A. Karam, MD6, Andres Henriquez, MD3, Travis Mckenzie, MD3, Alaa Sada, MD3, Isabelle Bourdeau, MD7, Jonathan Poirier, MD7, Anand Vaidya, MD MMSc8, Tiffany Abbondanza, BA8, Collen M. Kiernan, MD, MPH9, Sarika N. Rao, DO10, Oksana Hamidi, DO11, Nirupa Sachithanandan, MD12, Jose L. Chambo, MD1, Madson A. Queiroz, MD13, 14, Ana A F Hoff 14, Mouhammed A. Habra, MD4, Maria C.B.V. Fragoso, MD13,14.*  
1 - Division of Urology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil 2 - Division of Urology, Hospital Moriah, São Paulo, Brazil 3 - Division of Endocrinology, Mayo Clinic, Rochester, Minnesota 4 - Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas 5 - Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 6 - Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas 7 - Division of Endocrinology and Research Center, Centre hospitalier de l'Université de Montréal (CHUM), Montréal, Canada 8 - Center for Adrenal Disorders, Division of Endocrinology Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 9 - Division of Surgical Oncology and Endocrine Surgery, Vanderbilt University Medical Center, Nashville, Tennessee 10 - Division of Endocrinology, Mayo Clinic, Jacksonville, Florida 11 - Division of Endocrinology and Metabolism, University of Texas Southwestern Medical Center, Dallas, Texas 12 - Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne, Melbourne, Australia. 13 - Unidade de Suprarrenal, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil 14 - Instituto do Câncer do Estado de São Paulo da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
- 6.40 - 6.45  
The management of post-operative recurrences in patients with adrenocortical carcinoma (ACC): the experience of San Luigi Hospital.  
*A. CALABRESE<sup>o</sup>, S. Puglisi<sup>o</sup>, C. Borin<sup>o</sup>, V. Basile<sup>o</sup>, P. Perotti<sup>o</sup>, P. Berchialla<sup>o</sup>, A. Pia<sup>o</sup>, G. Reimondo<sup>o</sup>, M. Terzolo<sup>o</sup>.*  
<sup>o</sup>Department of Clinical and Biological Sciences, University of Turin.
- 6.45 - 6.50  
Expression of somatostatin receptors (SSTRs) in metastatic adrenocortical carcinoma  
*R. Maggio\*, P. Lardo\*, M. Lorusso<sup>o</sup>, V. Rufini<sup>o</sup>, A. STIGLIANO\**  
<sup>\*</sup>Endocrinology Sant'Andrea Hospital Sapienza University of Rome, <sup>o</sup>Gemelli Hospital Catholic University of Rome; Italy
- 6.50 - 6.55  
Genetic Dissection of Primary Aldosteronism in a Patient with Multiple Endocrine Neoplasia Type 1 (MEN1) and Concomitant Ipsilateral Adrenocortical Carcinoma and Adenoma.  
*S. PARISIEN-LA SALLE\*, G. Corbeil\*, M. Latour<sup>^</sup>, Z. El-Haffaf+, C. Duranceau#, A. Lacroix\*, P. Karakiewicz~ , I. Bourdeau\**  
<sup>\*</sup> Division of Endocrinology, Department of Medicine, Research Center, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, QC  
<sup>^</sup>Department of Pathology and Cellular Biology, CHUM, Montreal, QC  
<sup>+</sup>Division of Genetics, Department of Medicine, Research Center, CHUM, Montreal, QC  
<sup>#</sup>Division of Endocrinology, Department of Medicine, Chicoutimi Hospital, Université du Québec à Chicoutimi, Chicoutimi, QC  
<sup>~</sup>Division of Urology, Department of Surgery, CHUM, Montréal, QC

## PROGRAM October 1<sup>ST</sup>

- 6.55 - 7.00 Adult-onset adrenocortical cancer reveals Lynch-syndrome in up to 33.3% of cases  
*LAURY NICOLAS (1)(2)(6), Juliette Joubert (2)(3), Camille Darcha (2)(3), Sylvain Roumeau (1)(2)(4), Anne-Sophie Jarrousse (2)(3), Claude Darcha(2)(3), Laurent Guy (1)(2)(5), Jean-Paul Boiteux (1)(2)(5), Igor Tauveron(1)(2)(4), François Cornelis (1)(2)(6)*  
(1)Université Clermont-Auvergne  
(2)Centre Hospitalo-Universitaire de Clermont-Ferrand  
(3)Pathology department; (4)Endocrinology department  
(5)Urology department  
(6)Clinical Oncogenetics unit
- 7.00 - 7.05 Application of currently available tools for predicting survival in ACC patients: a single center study  
*P. MOURELATOS\*, A. Diamantopoulos\*, E. Kardalas\*, S. Kanellopoulou\*, V.I. Mitravela\*, M. Koulenti\*, E. Sampaniotti\*, E. Partsalaki\*, M. Giannakou\*, E. Botoula\*, G. Kyriakopoulos<sup>^</sup>, S. Kapisir<sup>o</sup>, S. Tsagarakis\*, D.A. Vassiliadi\**  
<sup>\*</sup>Dept. of Endocrinology, Diabetes and Metabolism, National Expertise Centre for Rare Endocrine Diseases, "Evangelismos" General Hospital of Athens, Athens  
<sup>^</sup>Dept. of Pathology, "Evangelismos" General Hospital of Athens, Athens  
<sup>o</sup>3rd Surgical Dept & Laparoscopic Unit, "Evangelismos" General Hospital of Athens, Athens
- 7.05 - 7.10 An impressive response to Pembrolizumab in a patient with stage IV ACC  
*M. KOULENTI\*, V.I. Mitravela \*, S. Kanellopoulou \*, P. Mourelatos \*, A. Diamantopoulos \*, E. Kardalas \*, E. Sampaniotti \*, E. Partsalaki \*, M. Giannakou \*, E. Dimitropoulos\*, E. Botoula \*, G. Kyriakopoulos ^, N. Soupos °, E. Lazaridou ~, I. Datsersis \*, S. Tsagarakis \*, D.A. Vassiliadi \**  
<sup>\*</sup>Dept. of Endocrinology, Diabetes and Metabolism, National Expertise Centre for Rare Endocrine Diseases, "Evangelismos" General Hospital, Athens, Greece  
<sup>^</sup>Dept. of Pathology, "Evangelismos" General Hospital, Athens, Greece  
<sup>o</sup>2nd Dept. of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece  
<sup>~</sup>Dept. of Radiology, "Evangelismos" General Hospital, Athens, Greece  
<sup>°</sup>Dept. of Nuclear Medicine and PET/CT Department, "Evangelismos" General Hospital, Athens, Greece
- 7.10 - 7.15 Adrenocortical cancer recurrence following initial transcutaneous biopsy: a rare demonstration of needle tract seeding.  
*N. YOUNES \*, I. Bourdeau \*, H. Olney ^, P. Perrotte ~, O. Prosmann °, M. Latour ~, D. Roberge □, A. Lacroix \**  
<sup>\*</sup> Division of Endocrinology, and Research Center, Centre hospitalier de l'Université de Montréal (CHUM)  
<sup>^</sup>Division of Hematology and Medical Oncology, Department of Medicine, ~Division of Urology, Department of Surgery, and Research Center, Centre hospitalier de l'Université de Montréal (CHUM)  
<sup>~</sup>Department of Radiology, and Research Center, Centre hospitalier de l'Université de Montréal (CHUM)  
<sup>°</sup>Department of Pathology, and Research Center, Centre hospitalier de l'Université de Montréal (CHUM)  
<sup>□</sup>Division of Radiation Oncology, and Research Center, Centre hospitalier de l'Université de Montréal (CHUM)
- 7.15 - 7.20 Combined treatment mitotane and ionizing radiations in adrenocortical carcinoma  
*P. Lardo\*, R. Maggio\*, M.F. Osti°, A. STIGLIANO\**  
<sup>\*</sup>Endocrinology Sant'Andrea Hospital Sapienza University of Rome, <sup>°</sup>Radiotherapy Sant'Andrea Hospital Sapienza University of Rome; Italy

# 8<sup>th</sup> INTERNATIONAL ADRENAL CANCER SYMPOSIUM

ALL TIMES STATED IN CEST  
(Central European Summer Time)

## PROGRAM October 1<sup>ST</sup>

Could we assess the functional status hormone secreting or non-secreting of the adrenal masses with regard to their Magnetic Resonance Imaging (MRI) characteristics?

*GAMZE AKKUS; Ferhat Can Piskin; Barış Karagun; Murat Sert; Mehtap Evran; Tamer Tetiker*

7.20 - 7.25

Gamze Akkus; M.D. Cukurova University, Faculty of Medicine, Division of Endocrinology, Adana, Turkey, Ferhat Can Piskin; M.D. Cukurova University, Faculty of Medicine, Division of Radiology, Adana, Turkey, Barış Karagun; M.D. Cukurova University, Faculty of Medicine, Division of Endocrinology, Adana, Turkey, Murat Sert; Prof. Cukurova University, Faculty of Medicine, Division of Endocrinology, Adana, Turkey, Mehtap Evran; M.D. Cukurova University, Faculty of Medicine, Division of Endocrinology, Adana, Turkey, Tamer Tetiker; Prof. Cukurova University, Faculty of Medicine, Division of Endocrinology, Adana, Turkey.

7.25 - 8.00

**Discussion**



## PROGRAM October 2<sup>ND</sup>

### 2.00 - 3.10 pm **I Session - Cushing and hypoadrenalism**

*Chairmen: Wiebke Arlt, Ohk-Hyun Ryu*

2.00 - 2.12	Glucocorticoids, microenvironment and potential therapeutic implication - Silviu Sbiera, Würzburg University
2.12 - 2.24	How bad is cortisol excess for patients with adrenal tumors? Irina Bancos, Mayo Clinic
2.24 - 2.36	Osilodrostat: a new player in the field Antoine Tabarin, University of Bordeaux
2.36 - 2.48	Detection and management of mitotane induced hypoadrenalism Rossella Libè, Cochin Hospital
2.48 - 3.10	<b>Discussion</b>
3.10 - 3.20	<b>Break</b>

### 3.20 - 4.30 pm **II Session - Management of advanced disease**

*Chairmen: Alice Levine, Massimo Mannelli*

3.20 - 3.32	Prognostic factors and their impact on practice Cristina Ronchi, University of Birmingham
3.32 - 3.44	What is oligometastatic ACC? And how to treat it? Julien Hadoux - Charles Roux, Gustave Roussy Institute
3.44 - 3.56	New markers and end-points to assess tumor response Eric Baudin - Matthieu Faron, Gustave Roussy Institute
3.56 - 4.08	Management of advanced adrenocortical cancer in children Raul C. Ribeiro, St. Jude Children's Research Hospital
4.08 - 4.30	<b>Discussion</b>
4.30 - 4.40	<b>Break</b>

# 8<sup>th</sup> INTERNATIONAL ADRENAL CANCER SYMPOSIUM

ALL TIMES STATED IN CEST  
(Central European Summer Time)

## PROGRAM October 2<sup>ND</sup>

### 4.40 - 5.40 pm **III Session - Future Perspectives**

*Chairmen: Katia Kiseljak-Vassiliades, Ronald De Krijger*

4.40 - 4.52 How to exploit preclinical models in the search of new drugs  
*Constanze Hantel, University Hospital of Zürich*

4.52 - 5.04 Next-generation molecular target therapies for adrenocortical carcinoma - Joakim Crona, Uppsala University

5.04 - 5.16 Is immunotherapy a game changer?  
*Mouhammed Habra, MD Anderson Cancer Center*

5.16 - 5.40 **Discussion**

5.40 - 5.50 **Break**

### 5.50 - 7.00 pm **IV Session - From disease care to patient care**

*Chairmen: Ana Hoff, Maurizio Castellano*

5.50 - 6.02 Do we know all on unwanted effects of mitotane?  
*Deborah Cosentini, University of Brescia - Soraya Puglisi, University of Torino*

6.02 - 6.14 A patient journey in the disease  
*Giampiero Mazzaglia, University of Milano Bicocca*

6.14 - 6.26 Role of patient reported outcomes  
*Rebecca Steenaard, Maxima Medical Center*

6.26 - 6.38 Emesis management and supportive care in advanced ACC receiving chemotherapy plus mitotane - Alfredo Berruti, University of Brescia

6.38 - 7.00 **Discussion**

7.00 - 7.10 **Break**

### **Keynote lecture**

*Chairmen: Felix Beuschlein, Franco Mantero*

7.10 - 7.40 pm Challenges in designing randomized clinical studies in rare diseases - Paolo Bruzzi, University of Genova

### **Update on collaborative studies and new proposals**

*Chairmen: Alfredo Berruti, Martin Fassnacht, Franco Mantero, Massimo Terzolo*

8.40 - 8.50 pm **Closing remarks**



ALL TIMES STATED IN CEST  
(Central European Summer Time)

## GENERAL INFORMATION

The 8th international adrenal cancer symposium will be held on an online platform [www.acc2021brescia.com](http://www.acc2021brescia.com)  
Pre-registration is needed to participate

## MEETING TIMES

All meeting times are CEST (Central European Summer Time)

## OFFICIAL LANGUAGE

English - no simultaneous translation

## MINIMUM SYSTEM REQUIREMENTS FOR PARTICIPATING IN THE VIRTUAL MEETING

### Hardware

- PC with audio (PC, Mac, Tablet, Smartphone)
- ADSL/4G Mobile internet connection

### Software

- Internet Browser, upgrade to the last 2 years
- Recommended browser: Google Chrome  
Microsoft® Internet Explorer is not supported anymore

## ONLINE REGISTRATION

Online pre-registration is mandatory  
Please submit your registration free of charge for the congress at [www.acc2021brescia.com](http://www.acc2021brescia.com)

# 8<sup>th</sup> INTERNATIONAL ADRENAL CANCER SYMPOSIUM

## INFORMAZIONI ECM

Il Webinar è stato accreditato **ECM** presso il Ministero della Salute

## PROVIDER

**IDEA-Z PROJECT IN PROGRESS S.R.L.** - Provider standard ID335

## ID EVENTO

**329930**

## OBIETTIVO NAZIONALE DI RIFERIMENTO

Applicazione nella pratica quotidiana dei principi e delle procedure dell'evidence based practice (EBM - EBN - EBP)

## TIPOLOGIA

Corsi in diretta su piattaforma multimediale dedicata (aula virtuale, webinar) FAD Sincrona

## PIATTAFORMA FAD

<https://www.acc2021brescia.com>

## DESTINATARI FORMAZIONE

### BIOLOGO

**FARMACISTA** Disciplina: FARMACIA OSPEDALIERA

### INFERMIERE

**MEDICO CHIRURGO** Discipline: ANATOMIA PATOLOGICA; CHIRURGIA GENERALE; ENDOCRINOLOGIA; MEDICINA INTERNA; MEDICINA NUCLEARE; ONCOLOGIA; RADIODIAGNOSTICA; RADIOTERAPIA; UROLOGIA; TECNICO SANITARIO LABORATORIO BIOMEDICO

## CREDITI ASSEGNATI

**N. 25,5** Crediti ECM per l'anno 2021

## REGOLAMENTO

Il corso viene svolto secondo il modello "FAD SINCRONA" e sarà trasmesso in diretta nei giorni 30 settembre, 1 ottobre e 2 ottobre 2021. Oltre al prezioso contributo degli esperti, ampio spazio sarà dedicato all'interattività tra docenti e discenti.

Al termine del percorso formativo è prevista la prova di verifica dell'apprendimento da compilare direttamente online, entro al massimo tre giorni. Sarà possibile conseguire i crediti formativi solo rispondendo correttamente ad almeno il 75% delle domande previste dalla prova di verifica.

Il limite massimo di ripetizioni della prova di verifica è stato stabilito nel numero di 5 tentativi, previa una nuova fruizione totale dei contenuti per ogni tentativo (dopo il primo tentativo, in caso di risposte esatte inferiori al 75%, sarà necessario consultare nuovamente l'intera didattica per poter accedere al tentativo successivo).

La generazione dell'Attestato ECM è subordinata al superamento della prova di verifica dell'apprendimento ed alla compilazione della scheda di valutazione dell'evento e del questionario di soddisfazione.

**ATTENZIONE:** sarà possibile compilare la prova di verifica dell'apprendimento solo fino alle ore 23.59 del 05 ottobre 2021. Dopo tale termine non sarà più possibile accedere alla prova e conseguire i crediti ECM.

We are grateful to the following Companies for their contribution  
to the success of the meeting



UNDER THE PATRONAGE OF:



UNIVERSITÀ  
DEGLI STUDI  
DI BRESCIA

Sistema Socio Sanitario



Regione  
Lombardia

ASST Spedali Civil



ORDINE  
MEDICI CHIRURGHI  
E ODONTOIATRI  
DELLA PROVINCIA  
DI BRESCIA



European Society  
of Endocrinology



Società Italiana  
Endocrinologia

**CME PROVIDER AND ORGANIZING SECRETARIAT**



**ideA-Z Project in progress S.r.l.**

Provider E.C.M. Standard n. 335

Abbiategrasso, Milan - Italy

Ph. +39 02 9462227

info@idea-z.it

PROJECT IN PROGRESS